Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Sustained localized delivery of FK506 to enhance peripheral nerve regeneration

EF 2016-17

Résumé
Injuries to the peripheral nervous system are common. Unlike neurons in the brain or spinal cord, peripheral nerves in the limbs have an innate ability to regenerate; however, nerve regeneration is slow and rarely complete. Patients with peripheral nerve injuries suffer reduced quality of life due to altered sensation, restricted motor function, chronic pain, and inability to return to work. Medications to enhance nerve recovery have been limited by systemic toxicity, high costs, and inconsistent effects. A promising agent is FK506 (tacrolimus), an FDA approved drug with potent neurotrophic effects. Unfortunately, systemic FK506 has undesirable effects such as immunosuppression, renal failure, and opportunistic infection. Recent biomedical engineering advancements in localized drug delivery systems (DDS) have renewed interest in FK506 to promote nerve regeneration. When administered to a site of nerve injury as a particulate suspension or within biosynthetic microspheres, sustained release of FK506 doubles the rate of nerve regeneration without systemic toxicity. FK506's unique ability to exert both neuroregenerative and immunosuppressive effects has great potential in nerve allograft transplantation for large nerve defects. Unfortunately, clinical use of nerve allografts is currently limited by concerns of systemic immunosuppression. Sustained localized delivery of FK506 using novel drug delivery systems represents a potentially revolutionary solution by exerting immunosuppression only at the allograft site, while simultaneously enhancing nerve regeneration through the allograft. We aim to investigate the efficacy of sustained localized FK506 with a nerve allograft in an acute large nerve gap injury rat model.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
367399
Name
Zuo Kevin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Sustained localized delivery of FK506 to enhance peripheral nerve regeneration
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Drug Delivery System; Electrical Stimulation; Fk506; Immunosupression; Nerve Gap; Nerve Injury; Nerve Reconstruction; Nerve Regeneration; Peripheral Nerve Injury; Tacrolimus
Abstract
Injuries to the peripheral nervous system are common. Unlike neurons in the brain or spinal cord, peripheral nerves in the limbs have an innate ability to regenerate; however, nerve regeneration is slow and rarely complete. Patients with peripheral nerve injuries suffer reduced quality of life due to altered sensation, restricted motor function, chronic pain, and inability to return to work. Medications to enhance nerve recovery have been limited by systemic toxicity, high costs, and inconsistent effects. A promising agent is FK506 (tacrolimus), an FDA approved drug with potent neurotrophic effects. Unfortunately, systemic FK506 has undesirable effects such as immunosuppression, renal failure, and opportunistic infection. Recent biomedical engineering advancements in localized drug delivery systems (DDS) have renewed interest in FK506 to promote nerve regeneration. When administered to a site of nerve injury as a particulate suspension or within biosynthetic microspheres, sustained release of FK506 doubles the rate of nerve regeneration without systemic toxicity. FK506's unique ability to exert both neuroregenerative and immunosuppressive effects has great potential in nerve allograft transplantation for large nerve defects. Unfortunately, clinical use of nerve allografts is currently limited by concerns of systemic immunosuppression. Sustained localized delivery of FK506 using novel drug delivery systems represents a potentially revolutionary solution by exerting immunosuppression only at the allograft site, while simultaneously enhancing nerve regeneration through the allograft. We aim to investigate the efficacy of sustained localized FK506 with a nerve allograft in an acute large nerve gap injury rat model.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Zuo, Kevin
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~